$577 Mln
$85 Mln
6.82
As on 31-Mar-2022 09:30 EDT
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
BioDelivery Sciences International Inc (BDSI)
| 80.32 | 0.72 | 81.49 | 49.07 | 1.79 | 24.42 | 8.73 |
|
S&P BSE Sensex*
| 8.52 | 1.18 | 4.83 | 13.64 | 21.78 | 12.71 | 12.73 |
|
S&P BSE Healthcare#
| 20.70 | -0.35 | 11.63 | 21.21 | 13.61 | 12.88 | 11.60 |
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|
|---|---|---|---|---|---|---|---|
|
BioDelivery Sciences International Inc (BDSI)
| -26.19 | -33.54 | 70.81 | 25.27 | 68.57 | -63.47 | -60.15 |
|
S&P BSE Sensex
| 21.99 | 15.75 | 14.38 | 5.87 | 27.91 | 1.95 | -5.03 |
|
S&P BSE Healthcare
| 20.87 | 61.45 | -3.55 | -5.89 | 0.49 | -12.88 | 15.06 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of BioDelivery Sciences International Inc (BDSI) stood at $ 325 Mln as on 31-Dec-21
The share price of BioDelivery Sciences International Inc (BDSI) is $5.590000 (NASDAQ) as of 31-Mar-2022 09:30 EDT. BioDelivery Sciences International Inc (BDSI) has given a return of 1.79% in the last 3 years.
BioDelivery Sciences International Inc (BDSI) has a market capitalisation of $ 577 Mln as on 31-Mar-2022. As per Value Research classification, it is a company.
The P/E (price to earnings) ratio of BioDelivery Sciences International Inc (BDSI) is 6.82 times as on 31-Mar-2022.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the BioDelivery Sciences International Inc (BDSI) and enter the required number of quantities and click on buy to purchase the shares of BioDelivery Sciences International Inc (BDSI).
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc.
The CEO & director of Mr. Jeffrey Allen Bailey. is BioDelivery Sciences International Inc (BDSI), and CFO & Sr. VP is Mr. Scott M. Plesha.
The promoters of BioDelivery Sciences International Inc (BDSI) have pledged 0% of the total equity as on Feb-22.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
529
|
|
|
178
|
|
|
119
|
|
|
56
|
| BioDelivery Sciences International Inc (BDSI) | Ratios |
|---|---|
|
Return on equity(%)
|
57.33
|
|
Return on capital employed(%)
|
44.77
|
|
Debt-to-equity ratio
|
0.02
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of BioDelivery Sciences International Inc (BDSI) was $85 Mln.
$577.05 Mln
$84.17 Mln
$84.86 Mln
$114.31 Mln
$4.62 Mln
$-- - --
103,229,000
NASDAQ: BDSI
Raleigh, NC
https://www.bdsi.com
BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its... products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies. It offers BELBUCA, a buprenorphine buccal film for the treatment of chronic pain; and Symproic, a peripherally acting mu-opioid receptor antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent opioid dosage escalation. The company also provides ELYXYB, a celecoxib oral solution for the treatment of migraine with or without aura in adults; and ONSOLIS, a fentanyl buccal soluble film for the management of breakthrough pain in cancer patients. BioDelivery Sciences International, Inc. was incorporated in 1997 and is headquartered in Raleigh, North Carolina. As of March 18, 2022, BioDelivery Sciences International, Inc. operates as a subsidiary of Collegium Pharmaceutical, Inc. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
